Victoza
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in…
Le diabete et son suivi representent un enjeu majeur en termes de sante publique. En effet, plus de 3 millions de personnes en…
Liraglutide (victoza, Novo Nordisk A/S) is human GLP-1 analogue developed by recombinant DNA technology. It is indicated along…
To study the efficacy of treatment with liraglutide in women with type 2 DM and NAFLD. A group of 10 women with type 2 DM and…
Aim. To study efficacy of treatment with liraglutide in women with type 2 diabetes (T2D) and obesity. Materials and methods. A…
WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • Liraglutide causes thyroid…
Liraglutide (Victoza) is a peptide produced by DNA recombinant technology, which presents 97% homology with human glucagon-like…
New molecular entity: Liraglutide (Victoza) was approved January 25, 2010 to improve blood sugar control in adults with type 2…
NEW DRUGS Victoza Is a New Contender In the Diabetes Arena A drug that helps the pancreas make more insulin has been approved…